## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.8% in mid entry zone (3.0-6.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (3.2%) confirms momentum alignment. Strong momentum (+3.1% 5-day acceleration). Outperforming sector by 7.0%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($64.50)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. DXCM DEADLINE: DexCom, Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Looming Deadline in Lawsuit**
- Source: FOX40 News | 20251210T010925 | Neutral | Relevance: 100%
-  Investors in DexCom, Inc. (NASDAQ:DXCM) are urged to contact Kirby McInerney LLP regarding a securities fraud class action lawsuit, with a lead plaintiff deadline of December 26, 2025. The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 glucose monitors, leading to inaccurate readings, health risks, and a decline in stock prices due to regulatory scrutiny and downgrades. The firm is seeking to represent investors who suffered losses during the period of January 8, 2024, through September 17, 2025.

**2. Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class Action â€“ Contact The Gross Law Firm to Learn More**
- Source: GlobeNewswire | 20251209T070844 | Neutral | Relevance: 99%
-  The Gross Law Firm has issued a notice urging shareholders of DexCom, Inc. (NASDAQ: DXCM) who lost money during the period of January 8, 2024, to September 17, 2025, to join a class-action lawsuit. The complaint alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, rendering them less reliable and posing health risks, which the company allegedly downplayed. Shareholders have until December 26, 2025, to seek a lead plaintiff appointment in this class action concerning alleged materially false and/or misleading statements by DexCom.

**3. DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: Fox 59 | 20251209T120851 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made materially false and misleading statements regarding unauthorized design changes to its G6 and G7 devices, compromising their reliability and presenting health risks. Investors with substantial losses have until December 26, 2025, to seek appointment as lead plaintiff.

**4. DXCM Deadline: DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit**
- Source: WTNH.com | 20251210T210759 | Neutral | Relevance: 99%
-  The Rosen Law Firm is reminding investors who purchased DexCom, Inc. (NASDAQ: DXCM) securities between July 26, 2024, and September 17, 2025, that they have until December 29, 2025, to seek appointment as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that DexCom made false and/or misleading statements regarding unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users. Investors who suffered damages can join the class action to potentially recover compensation.

**5. Shareholders SueWallSt in New Class Action Against DexCom, Inc. - Act Now**
- Source: WJBF | 20251209T220753 | Neutral | Relevance: 99%
-  A class action lawsuit has been filed against DexCom, Inc. on behalf of investors who allegedly suffered financial losses due to securities fraud between January 8, 2024, and September 17, 2025. Investors are encouraged to contact Levi & Korsinsky for more information about joining the lawsuit.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 7.6% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (2 raises, avg +11%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.0B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 27.7 |
| Current P/E | 33.4 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.7% to 4.8% (+3.1% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 86th percentile. MRS_5 at 3.2% confirms short-term momentum alignment. Outperforming sector by 7.0pp, stock-specific strength. Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (0.92), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.75% (CS: 86) | Strong |
| RSI_14 | 68.6 | Neutral |
| MACD Histogram | 0.92 | Bullish |
| vs SMA20 | 1.097x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 0.924x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $68.94
- **Stop Loss:** $64.50 (6.4% risk)
- **Target:** $75.60 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 310
- **Position Value:** $21,371.40
- **Portfolio %:** 21.37%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*